Report published September 28, 2026
Longevity Weekly Pulse #75: Key Takeaways from a European Health Care Conference – UBS
UBS · September 28, 2026
Following attendance at a European healthcare broker conference, UBS highlights 2026 as a transition period setting up 2027 for earnings reacceleration led by new drug launches. The report emphasizes the necessity of pipeline diversification and bolt-on acquisitions to offset impending patent cliffs later this decade.
Read the remaining 4 pages
Finvaulta summarizes UBS's analysis. Attribute opinions, forecasts, time-sensitive values, and chronology to the issuer and report date; do not treat this page as an independent verification or a current market-data source.
Key Takeaways
- 1.2026 is seen as a transition year, with 2027 positioned as the next phase of earnings reacceleration driven by new drug launches.
- 2.Pipeline breadth is essential; diversified innovation portfolios are preferred over single-product reliance to manage upcoming patent expirations later this decade.
- 3.Pharma companies are expected to ramp up bolt-on M&A ($5-10bn range) over the next 12-18 months, while AI adoption aids operations and workflow rather than late-stage clinical R&D success.
Table of Contents
- Thoughts of the week
- Novartis: Confidence intact despite recent pipeline setback
- Roche: Multiple opportunities emerging
- AstraZeneca: Confidence in CVRM pipeline
- Novo Nordisk: A show-me story
- Chart of the week
- Risk Table
- 12 month CIO selection changes history
Report data
Figure 1: EU health care valuation (NTM P/E MSCI European health care vs. MSCI AC Europe)
| Metric | Estimate | Context |
|---|---|---|
| Novartis Consensus Top-Line Sales Growth Expectation | 4.0% | Novartis expects its updated medium-term guidance to imply sales growth above consensus expectations of 4%. |
| Novo Nordisk Targeted Bolt-on Acquisition Size | 5.0 USD billion | Novo Nordisk stated a preference for smaller bolt-on transactions of USD 5-10bn rather than transformational deals. |
| Eli Lilly & Co. Longevity Equity Preference List Weight | 12.27% | Portfolio weight in the Longevity Equity preference list. |
| AstraZeneca China Revenue Contribution | 13.0% | Share of revenues derived from China, cited as a specific risk factor due to government investigations. |
Reports in this series
Longevity Weekly Pulse is shown in chronological order through this edition, published on September 28, 2026.
Part of the Longevity Weekly Pulse series — view all 12 editions
Looking for the latest edition? Transformational Innovation Opportunities (TRIO) en 1667326 (Oct 6, 2026)
Access the full report
And others from the leading tier 1 banks.
Free account: read previews and a daily allowance of full reports. Pro removes the daily limit.